Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Plasmalogens and Alzheimer's disease: a review.

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1. Review.

2.

Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling.

Hossain MS, Ifuku M, Take S, Kawamura J, Miake K, Katafuchi T.

PLoS One. 2013 Dec 20;8(12):e83508. doi: 10.1371/journal.pone.0083508. eCollection 2013.

3.

Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Dunys J, Valverde A, Checler F.

J Biol Chem. 2018 Oct 5;293(40):15419-15428. doi: 10.1074/jbc.R118.003999. Epub 2018 Aug 24. Review.

4.

MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.

Liu CG, Wang JL, Li L, Wang PC.

Int J Mol Med. 2014 Jul;34(1):160-6. doi: 10.3892/ijmm.2014.1780. Epub 2014 May 13.

PMID:
24827165
5.

Neuronal Orphan G-Protein Coupled Receptor Proteins Mediate Plasmalogens-Induced Activation of ERK and Akt Signaling.

Hossain MS, Mineno K, Katafuchi T.

PLoS One. 2016 Mar 2;11(3):e0150846. doi: 10.1371/journal.pone.0150846. eCollection 2016.

6.

Beneficial Effect of Astragaloside on Alzheimer's Disease Condition Using Cultured Primary Cortical Cells Under β-amyloid Exposure.

Chang CP, Liu YF, Lin HJ, Hsu CC, Cheng BC, Liu WP, Lin MT, Hsu SF, Chang LS, Lin KC.

Mol Neurobiol. 2016 Dec;53(10):7329-7340. Epub 2015 Dec 22.

PMID:
26696494
7.

Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease.

Williams RJ, Spencer JP.

Free Radic Biol Med. 2012 Jan 1;52(1):35-45. doi: 10.1016/j.freeradbiomed.2011.09.010. Epub 2011 Sep 17. Review.

PMID:
21982844
8.

Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease.

Rothhaar TL, Grösgen S, Haupenthal VJ, Burg VK, Hundsdörfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO.

ScientificWorldJournal. 2012;2012:141240. doi: 10.1100/2012/141240. Epub 2012 Apr 1.

9.

BACE inhibition-dependent repair of Alzheimer's pathophysiology.

Keskin AD, Kekuš M, Adelsberger H, Neumann U, Shimshek DR, Song B, Zott B, Peng T, Förstl H, Staufenbiel M, Nelken I, Sakmann B, Konnerth A, Busche MA.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):8631-8636. doi: 10.1073/pnas.1708106114. Epub 2017 Jul 24.

10.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
11.

Dyrk1 inhibition improves Alzheimer's disease-like pathology.

Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, Smith B, Hulme C, Dunckley T, Meechoovet B, Caccamo A, Oddo S.

Aging Cell. 2017 Oct;16(5):1146-1154. doi: 10.1111/acel.12648. Epub 2017 Aug 4.

12.

Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.

Ma QH, Jiang LF, Mao JL, Xu WX, Huang M.

Mol Med Rep. 2018 Mar;17(3):4113-4119. doi: 10.3892/mmr.2017.8289. Epub 2017 Dec 18.

PMID:
29257340
13.
14.

Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease.

He P, Cheng X, Staufenbiel M, Li R, Shen Y.

PLoS One. 2013;8(2):e55091. doi: 10.1371/journal.pone.0055091. Epub 2013 Feb 6.

15.

MicroRNA-29c targets β-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo.

Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G, Yu D, Pan S.

Mol Med Rep. 2015 Aug;12(2):3081-8. doi: 10.3892/mmr.2015.3728. Epub 2015 May 5.

PMID:
25955795
16.

Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.

Tokutake T, Kasuga K, Yajima R, Sekine Y, Tezuka T, Nishizawa M, Ikeuchi T.

J Biol Chem. 2012 Oct 12;287(42):35222-33. doi: 10.1074/jbc.M112.348300. Epub 2012 Aug 21.

17.

Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease.

Hamm V, Héraud C, Bott JB, Herbeaux K, Strittmatter C, Mathis C, Goutagny R.

Sci Adv. 2017 Feb 24;3(2):e1601068. doi: 10.1126/sciadv.1601068. eCollection 2017 Feb.

18.

Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease.

Gupta S, Yadav K, Mantri SS, Singhal NK, Ganesh S, Sandhir R.

Mol Neurobiol. 2018 Dec;55(12):8916-8935. doi: 10.1007/s12035-018-0985-0. Epub 2018 Apr 3.

PMID:
29611103
19.

APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.

Bignante EA, Ponce NE, Heredia F, Musso J, Krawczyk MC, Millán J, Pigino GF, Inestrosa NC, Boccia MM, Lorenzo A.

Neurobiol Aging. 2018 Apr;64:44-57. doi: 10.1016/j.neurobiolaging.2017.12.013. Epub 2017 Dec 20.

PMID:
29331876
20.

Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice.

Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT.

J Nutr. 2009 Oct;139(10):1987-93. doi: 10.3945/jn.109.109785. Epub 2009 Aug 5.

PMID:
19656855

Supplemental Content

Support Center